

MINUTES OF A REGULAR MEETING
OF THE MASSACHUSETTS LIFE SCIENCES CENTER
BOARD OF DIRECTORS

February 15, 2023

Hybrid: In-person at MLSC Offices and Virtual via Microsoft Teams

1. Call to Order: Co- Chairperson Catharine Hornby

Catharine Hornby, presiding as chairperson of the Board of Directors (the “Board”) of the Massachusetts Life Sciences Center (the “MLSC” or “Center”) called the meeting to order. The meeting, having been duly convened, was ready to proceed with its business. Ms. Hornby conducted roll call, members Hao, Hornby and Chen were present in-person, Members Kearney, Randhawa, and Scarlett were connected virtually, and Mr. Stuart Abelson was absent from the meeting.

2. Approval of December Meeting Minutes: Co- Chairperson Catharine Hornby

The Board reviewed the minutes of the December 14, 2022 Board meeting. Upon motions duly made, seconded and carried, the Board approved the minutes.

3. Chair Updates: Co-Chairpersons Yvonne Hao and Catharine Hornby

Secretary Hao stated how grateful and motivated she is for the role of Secretary of Economic Development. Secretary Hao noted that this is her first MLSC Board meeting, and she is excited to engage with the board and the Center. She continued by outlining her and the Administrations priorities. Secretary Hao explained the first priority is keeping Massachusetts at the forefront of life sciences globally, and doing everything we can to not only protect what we have but also lengthening MA lead in the life sciences sector. Secretary Hao then noted that the Economic Development and Planning Process is underway, and she will be looking for input from the Board and the Center.

Undersecretary Catharine Hornby began her remarks by noting this is her final meeting as Co-Chairperson of the Board. Ms. Hornby stated that she has been impressed with the Center as a whole, the dedication of the Board and the motivation and dedication of the Center’s leadership and staff. Ms. Hornby said it has been a pleasure to serve as co-chairperson and is confident in the continued success of the organization.

4. CEO Report: Kenneth Turner, President and CEO

Mr. Turner began his remarks by recognizing the hard work and diligent professionalism of his team. After Mr. Turner gave a brief overview of the robust agenda for the meeting, Mr. Turner provided a brief lookahead for 2023, commenting that there are big and momentous goals for the MLSC in the year ahead. Mr. Turner then recognized departing Co-Chairperson, Catharine Hornby, stating it has been a pleasure working with her, and that we are all inspired by her. Mr. Turner completed his remarks with a recap of the Policy Breakfast, reauthorization plans and the ARPA-H initiative.

5. Financial Update, Peter Breiling, Vice President of Finance

Mr. Breiling provided an update on the MLSC financials through the first half of FY2023, beginning with a highlight of the financial position of the Center. Mr. Breiling reported that operating expenses were 16% below budget for the first half of FY2023, but anticipates operating expenses to remain at the projected budget by the end of the Fiscal Year. Mr. Breiling indicated that the CNS infusion of funding has been critical to the Investment Fund and operating expenses. There were no questions for Mr. Breiling, but some commentary on how a line item in budget going forward versus CNS would benefit the Center.

6. Guest Presentation: Azadeh Khanicheh, Ph.D., Co-Founder and President of Envision Endoscopy

Guest Speaker, Azadeh Khanicheh, was introduced to the Board as a former MassNextGen awardee and Seed Fund awardee. Dr. Khanicheh provided a detailed presentation on the technology underlying the company, progress of the product development and market opportunity.

7. MassNextGen 2.0 Allocation Dr. Katya Mantrova, MD, PhD, Director, Industry Strategy and Investments

Dr. Mantrova began her presentation on the MassNextGen 2.0 program with an overview of the MassNextGen initiative and program goals. Dr Mantrova then provided details on how the program aligns with the Center’s strategic framework. After providing information on the past successes of the inaugural MassNextGen program, Dr. Mantrova provided specific and detailed information on the next iteration of the program: MassNextGen 2.0, including the expanded applicant pool and extended capital financing that

will be available to awardees. After an overview of the planned program year for each round of the MassNextGen 2.0 program, Dr. Mantrova described the planned expansion of the program and the different levels of sponsorship packages that will be available to prospective sponsors. Dr. Mantrova requested that the Board approve a commitment of \$1.5M over 5 years to promote greater diversity and parity in life science entrepreneurship within the Commonwealth.

Dr. Mantrova fielded questions from the Board, including questions about the mentoring aspect of the program and sponsorship sources. There being no further discussion, the Board moved to a vote.

Upon a motion duly made, seconded and carried by roll call vote, the Board resolved to approve the allocation of \$1,500,000 to the MassNextGen 2.0 Program.

8. Angel Investor Tax Credit: 2022 Round, Elizabeth Kennedy, VP of Business Development and Strategy
Ms. Kennedy addressed the Board regarding the 2022 Angel Investor Tax Credit. Ms. Kennedy provided an overview of the Angel Investor Tax Credit program, including eligibility requirements and the general rules applied to the program. Ms. Kennedy explained the tax credit limitations and the application process, which included conditionally approving applications pending the Board's review and approval. Ms. Kennedy then informed the Board of the post-award process.

Ms. Kennedy presented to the Committee a review of the 2022 round, explaining fifty-eight applications were submitted, with 8 applications deemed ineligible based on the eligibility criteria, resulting in 50 applications approved conditionally. Ms. Kennedy presented the statistics for the 20 eligible companies that were target investments. After fielding questions from the Board and a discussion on the goals and mission of the program, Ms. Kennedy proposed a total of \$505,789.24 to be allocated to Angel Investors for the tax credit.

Upon a motion duly made, seconded and carried by roll call vote, the Board resolved to approve the allocation of \$505,789.24 to the Angel Investors as presented for the tax credit, and to certify each of the Companies be Certified Life Sciences pursuant to M.G.L. Ch23I.

9. 2023 M2D2 \$200K Challenge Cinar Efe Sumer, Program Associate, Industry Strategy and Investments
Mr. Sumer presented the opportunity to sponsor the 2023 M2D2 \$200K Challenge, similar to past years. Mr. Sumer provided a comprehensive overview of the history of MLSC support for the M2D2 Challenge and successful outcomes for past awardees. Mr. Sumer detailed how the MLSC will be represented at the Challenge, with President and CEO, Kenn Turner participating in a fireside chat at the opening of the event, and MLSC having a representative on the judging panel. Mr. Sumer requested Board of Directors allocate \$50,000 to an award at the 2023 M2D2 Challenge.

Upon a motion duly made, seconded and carried by roll call vote, the Board resolved to allocate \$50,000 to the 2023 M2D2 \$200K Challenge

10. Presentation: RED (Research Equipment Database), Dr. Carla Reimold, Ph.D, Vice President of Industry Strategy and Investments

Dr. Reimold provided a detailed presentation on the Research Equipment Database (RED), and the key metrics tracking for evaluating program impact. Dr. Reimold explained the capital inventory project that collected data on capital equipment purchased through MLSC capital grants. Dr. Reimold described how RED is a resource that allows us to track life sciences ecosystem impact through the database.

11. Research Infrastructure Program: Rosalee Maffett, Program Manager, Industry Strategy and Investments

Ms. Maffett presented the 2023 Research Infrastructure Program, starting with the strategic rationale for the program and how it aligns with the Center's strategic framework. Ms. Maffett provided an explanation of the program history, an overview of the application and review process and independent review panel process in selecting the proposed awardees. Ms. Maffett also explained the high demand for this program, and the additional capital allocation for this round of the program as a result of lower demand for the other capital programs this year.

Ms. Maffett provided an overview of the applications submitted this year, with a total of 22 applications received. The independent review panel selected eight proposed awardees. Ms. Maffett provided details on each of the proposed awardees, including the project and requested equipment purchases.

A discussion followed, allowing the Board Members the opportunity to pose questions about the program and the proposed awardees, and Ms. Maffett provided information to the satisfaction of the Board members. Ms. Maffett requested funding for the 2023 Research Infrastructure Program awardees in the total amount of \$18,152,398 MLSC matching funds for the projects as presented at the meeting and the Research Infrastructure Program Presentation.

Upon a motion duly made, seconded and carried by roll call vote, the Board resolved to allocate up to \$18,152,398 to the selected awardees of the 2022 Research Infrastructure program.

Having no further business before the committee, Ms. Hornby called the meeting adjourned

Materials used during Meeting:

- Agenda
- CEO Update Presentation
- Financial Update
- Draft Minutes from December 2022 Board of Directors Meeting
- Presentation: Angel Investor Tax Credit: 2022 Round
- Presentation: Research Infrastructure Program
- Presentation: 2023 M2D2 \$200K Challenge
- Presentation: Guest Speaker
- Presentation: MassNextGen 2.0
- Presentation: Research Equipment Database (RED)